Source: Annual Congress 2005 - Pleural effusions and pneumothorax
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
M. Gavrilovski, G. Breskovska, K. Busletic, B. Kaeva (Skopje, Fyrom). Clinical evaluation of NSE, CYFRA 21-1, CEA and MCA at patients (pts.) with metastatic pleural effusion (PE). Eur Respir J 2005; 26: Suppl. 49, 2872

Member's Comments

No comment yet.

Related content which might interest you: Clinical significance of CEA, NSE, CYFRA 21-1 in serum and pleural fluid for the diagnosis of malignant pleural effusion associated with primary lung cancer Source: Eur Respir J 2004; 24: Suppl. 48, 528s Year: 2004 Tumor markers (TM) CEA, CYFRA 21-1,MCA and NSE in pleural effusion(PE) at malignant mezothelioma and metastatic tumor of pleura Source: Eur Respir J 2002; 20: Suppl. 38, 439s Year: 2002 Tumor markers (TM) CEA, MCA and CA 19-9 in pleural effusion (PE) at malignant mezothelioma and methastatic tumour of pleura Source: Eur Respir J 2003; 22: Suppl. 45, 61s Year: 2003 Diagnostic value of CYFRA 21-1, CEA, CA19-9, CA 15-3, and CA 125 assay in pleural effusions: analysis of 116 cases and review of the literature Source: Eur Respir J 2005; 26: Suppl. 49, 73s Year: 2005 The usefulness of Cyfra 21-1 as a disease marker in malignant pleural mesothelioma (MPM) Source: Eur Respir J 2006; 28: Suppl. 50, 85s Year: 2006 Comparative evaluation of CA-125, CA 19-9, CA 15-3 and CEA in exudative benign and malignant pleural effusion Source: Annual Congress 2010 - Novel approach in diagnosis and treatment of pleural effusions Year: 2010 Diagnostic utility of pleural CEA and CYFRA 21-1 for malignant pleural effusions Source: Eur Respir J 2003; 22: Suppl. 45, 60s Year: 2003 Evaluation of pleural fluid levels and pleural-serum ratio of the tumor markers CEA, CA 15,3, CA 19,9, CA 72,4, CA 125 and CYFRA 21,1 in the diagnosis of malignant pleural effusion Source: Annual Congress 2010 - Current issues in malignant pleural diseases Year: 2010 Response to cancer chemotherapy (CTh) in patients (pts) with non-small cell lung cancer (NSCLC) according to their serum levels of chosen tumor markers (CYFRA 21-1 (CY21), CEA and NSE) Source: Eur Respir J 2001; 18: Suppl. 33, 377s Year: 2001 Tumour marker (TM) CA 19-9 in pleural fluid at patients with malignant and paramalignant pleural effusion (PE) Source: Eur Respir J 2001; 18: Suppl. 33, 387s Year: 2001 Diagnostic value of linear combination of CYFRA 21-1 and carcinoembryonic antigen in malignant pleural effusions Source: Eur Respir J 2004; 24: Suppl. 48, 528s Year: 2004 Diagnostic utility of CYFRA 21-1 and carcinoembryonic antigen as a tumour markers in malignant pleural effusions Source: Eur Respir J 2001; 18: Suppl. 33, 397s Year: 2001 Prognostic and predictive value of cytokeratin-19 fragments (Cyfra 21-1), carcinoembryonic antigen (CEA) and human chorionic gonadotropin (bHCG) in 138 NSCLC patients - 5 years of observation Source: Eur Respir J 2002; 20: Suppl. 38, 73s Year: 2002 The diagnostic value of the examination of the tumor markers CYFRA 21-1, NSE, TPA and CEA from the bronchoalveolar lavage fluid in diffuse pulmonary disorders Source: Annual Congress 2008 - Role of bronchoalveolar lavage in studying the pathophysiology of interstitial lung disease Year: 2008 CEA, Cyfra 21.1 and NSE levels in malignant and benign pleural effusion Source: Eur Respir J 2002; 20: Suppl. 38, 273s Year: 2002 Post operative dynamism of NSCLC tumor markers (CEA, CYFRA 21.1, NSE, TK, TPS) Source: Eur Respir J 2006; 28: Suppl. 50, 719s Year: 2006 Is it possible to predict response to cancer chemotherapy (CTh) in patients (pts) with non-small cell lung cancer (NSCLC) on the basis of serum CYFRA 21-1 level (sCY21)? Source: Eur Respir J 2002; 20: Suppl. 38, 74s Year: 2002 Clinical contribution of tumor marker CYFRA 21-1 in evaluation of response to therapy in NSCLC patients Source: Eur Respir J 2001; 18: Suppl. 33, 377s Year: 2001 The investigation of diagnostic value of serum reactive protein (CRP) in patients with pleural effusion Source: Eur Respir J 2006; 28: Suppl. 50, 374s Year: 2006 Evaluation of intrapericardial cisplatin (CIS) administration in cases with recurrent malignant pericardial effusion (MPE) in pts with lung cancer Source: Eur Respir J 2003; 22: Suppl. 45, 63s Year: 2003